Myelin Regeneration
Rebuild the myelin insulation that lets nerves carry signals
The goal is to regrow myelin — the insulating sheath around nerve fibers that lets signals travel fast and true — so that conditions which strip myelin away, like multiple sclerosis, can be met with repair, not just slowed inflammation.
Nerve fibers are wrapped in myelin, the insulation that lets electrical signals race along them. When myelin is lost — as in multiple sclerosis, where the immune system attacks it — signals slow or fail, causing weakness, numbness, vision loss, and disability. Today’s MS therapies reduce the immune attack but do not repair the myelin already lost. Regrowing myelin — remyelination — could restore function. It is the repair-focused companion to nerve regeneration.
We are building the capability to regrow lost myelin and restore signal flow: prompting the body’s own myelin-making cells to rebuild the sheath, and protecting myelin from further loss — turning MS and related conditions from managed toward repaired.
Rebuilding the nerve’s insulation
Prompting the body to remyelinate Clinical
The body’s own myelin-making cells (oligodendrocyte precursors) can be prompted to mature and rebuild myelin — measurable remyelination has been shown on imaging in MS trials.
Protecting existing myelin Demonstrated
Reducing the immune attack on myelin preserves what remains while repair strategies mature.
Cell-based myelin repair Frontier
Cell therapies to replace lost myelin-making cells are an active research direction.
Cited as evidence the capability is real — not as partners or endorsers.
Universities & institutes
University of Cambridge (Cambridge Centre for Myelin Repair) and academic MS and remyelination research centers worldwide.
Government & programs
National Institute of Neurological Disorders and Stroke (NINDS, NIH) · NIH and MS-focused research programs.
Enabling science base
oligodendrocyte precursor biology · remyelination pharmacology · myelin imaging biomarkers · neural cell therapy.
The technologies: approaches that prompt the body’s myelin-making cells to mature and rebuild myelin; myelin imaging biomarkers that let researchers see repair; cell therapies to replace lost myelin cells; and neuroprotection that preserves myelin while repair advances.
Remyelination seen on imaging Clinical trials
Multiple MS trials have shown measurable remyelination on advanced imaging — evidence the body can be prompted to rebuild myelin.
Functional benefit unproven Frontier
So far, imaging repair has not yet translated into measurable improvement in disability or vision — proving functional benefit is the next hurdle.
Cell-based approaches Frontier
Replacing lost myelin-making cells is advancing in research.
The honest challenges, stated plainly: remyelination has been seen on imaging markers, but it has not yet been shown to restore function (disability, vision) in people — that is the key unproven step, and effects so far have been small. It may take years of longer trials to prove functional benefit. And repair must reach the right fibers. Slowing the immune attack is clinical; myelin repair is an early, promising frontier, and we will not overstate it.
The future, fully built
A person losing function as myelin erodes has it rebuilt: the body’s own myelin-making cells prompted to re-insulate nerve fibers, signals restored, function recovered rather than only protected. Myelin becomes something we regrow, turning demyelinating disease from managed toward repaired.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Remyelination on imaging
Multiple MS trials showed measurable remyelination on advanced imaging. Stage: Clinical (trials, surrogate markers).
Clemastine + metformin trial
A randomized trial showed significantly increased myelin repair on imaging; effects small, no functional improvement yet at six months. Stage: Clinical (trials).
Functional benefit
Imaging repair has not yet translated to measurable disability or vision improvement — the key unproven step. Stage: Frontier.
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. Functional benefit from remyelination is not yet proven in people; nothing here claims it is.
Help build this future
Every signature grows the movement to make myelin regeneration real — and free at the point of need.